[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349267-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349267-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","patients-with-stage-iii-plcnec-advocated-for-radiotherapy-combined-with-chemotherapy-while-with-stage-iv-focus-on-individualized-management-evidence-from-seer","Patients With Stage III PLCNEC Advocated for Radiotherapy Combined With Chemotherapy While With Stage IV Focus on Individualized Management: Evidence From SEER","","PLCNEC is a rare, highly aggressive lung cancer with poor prognosis. This study assesses whether adding radiotherapy to chemotherapy improves outcomes in stage III–IV PLCNEC and builds individualized prediction tools using population-level evidence from the SEER database. Data from 1,086 chemotherapy-treated patients (2004–2015) were analyzed with propensity score matching, Kaplan–Meier survival comparisons, Cox regression, and validated prognostic nomograms for OS and CSS.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/patients-with-stage-iii-plcnec-advocated-for-radiotherapy-combined-with-chemotherapy-while-with-stage-iv-focus-on-individualized-management-evidence-from-seer/349267/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/patients-with-stage-iii-plcnec-advocated-for-radiotherapy-combined-with-chemotherapy-while-with-stage-iv-focus-on-individualized-management-evidence-from-seer/349267.png","ImageObject",300,407,{"name":42,"@type":43},"supergirl","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is PLCNEC and why is treatment challenging?","Question",{"text":63,"@type":64},"PLCNEC is a rare, highly aggressive lung cancer with poor prognosis. Its clinical features and diagnosis are difficult, and optimal treatment strategies are not clearly established.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study evaluate the effect of radiotherapy with chemotherapy?",{"text":68,"@type":64},"The study analyzed 1,086 chemotherapy-treated PLCNEC patients from SEER, applied propensity score matching to reduce confounding, and used Kaplan–Meier survival curves and Cox regression to compare outcomes and identify prognostic factors.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about survival in stage III–IV patients?",{"text":72,"@type":64},"Chemotherapy plus radiotherapy was associated with improved overall survival (OS) and cancer-specific survival (CSS) versus chemotherapy alone in stage III–IV patients. Stage IV benefit appeared more context-dependent.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349267,1790646590,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer Reports  \nORIGINAL ARTICLE  OPEN ACCESS   \nPatients With Stage III PLCNEC Advocated for Radiotherapy Combined With Chemotherapy While With Stage IV Focus on Individualized Management: Evidence From SEER  \nYuze Zhao1  | Guantong Liu1  | Haitao Li1  | Yu Li1  | Ting Lin2  | Zefeng Xie1   \n1The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China | 2Chenghai People Hospital, Shantou, Guangdong, China  \nCorrespondence: Zefeng Xie ([zefengxie@sina.com](zefengxie@sina.com))  \nReceived: 27 April 2025 | Revised: 20 April 2026 | Accepted: 29 April 2026  \nKeywords: chemoradiotherapy | nomogram | prognosis | pulmonary large cell neuroendocrine carcinoma | survival analysis  \nABSTRACT  \nBackground: PLCNEC is a rare and highly aggressive lung cancer with a poor prognosis. Multimodal therapy, primarily chemotherapy-based, is the standard for advanced PLCNEC, but the role of radiotherapy remains unclear.  \nMethods: We analyzed 1086 PLCNEC patients receiving chemotherapy from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. Propensity score matching (PSM) was applied to adjust baseline confounding variables. Kaplan–Meier survival curves were constructed and compared to assess survival differences. Cox proportional hazards regression models were employed to evaluate prognostic factors. Predictive nomograms were developed and validated to predict individual survival probabilities and facilitate clinical decision-making.  \nResults: Chemotherapy combined with radiotherapy was associated with improved OS and CSS compared with chemotherapy alone in stage III–IV PLCNEC patients (p \u003C 0.05) . Sex, N stage, M stage, surgical treatment, and radiotherapy were identified as independent prognostic factors. Nomograms developed demonstrated strong predictive performance, with areas under the curve (AUCs) for OS of 0.720, 0.821, and 0.847 at 1, 3, and 5 years, respectively, and for CSS of 0.733, 0.800, and 0.810 at the corresponding time points. Subgroup analyses suggested that selected patients may derive differential benefit from chemoradiotherapy. Conclusion: Radiotherapy is associated with improved survival outcomes in stage III PLCNEC patients receiving chemotherapy, whereas its role in stage IV disease appears more context-dependent and warrants individualized consideration. The proposed nomograms provide complementary prognostic information to support individualized clinical decision-making.  \n1 | Introduction  \nAccording to the latest GLOBOCAN estimates, lung cancer remains the most commonly diagnosed cancer and the leading cause of cancer-related death worldwide [1] . In 2022, almost 2.5 million new cases were diagnosed globally, and more than 1.8 million deaths were attributed to the disease, representing about 12% of all new cancers and around 18%–19%  \nof all cancer deaths [2] . Traditionally, lung cancer has been categorized into two primary histological subtypes: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) . Pulmonary neuroendocrine tumors, a heterogeneous subtype of lung cancer characterized by neuroendocrine morphology, immunohistochemistry revealing neuroendocrine differentiation, a high mitotic rate (> 10 mitosis·2 mm−2) and non-small cell cytological features, account for approximately 3% of lung  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Cancer Reports published by Wiley Periodicals LLC.  \nCancer Reports, 2026; 9:e70573 1 of 21  \n[https://doi.org/10.1002/cnr2.70573](https://doi.org/10.1002/cnr2.70573)  \ncancers [3–5] . Despite their relatively low incidence, highgrade pulmonary neuroendocrine carcinomas contribute disproportionately to lung-cancer–related mortality due to their aggressive biological behavior and tendency to present at advanced stages. ","cbCaie27y78nvHyZ","https://ap.wps.com/l/cbCaie27y78nvHyZ","pdf",4062618,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is PLCNEC and why is treatment challenging?\",\"answer\":\"PLCNEC is a rare, highly aggressive lung cancer with poor prognosis. Its clinical features and diagnosis are difficult, and optimal treatment strategies are not clearly established.\"},{\"question\":\"How did the study evaluate the effect of radiotherapy with chemotherapy?\",\"answer\":\"The study analyzed 1,086 chemotherapy-treated PLCNEC patients from SEER, applied propensity score matching to reduce confounding, and used Kaplan–Meier survival curves and Cox regression to compare outcomes and identify prognostic factors.\"},{\"question\":\"What did the results show about survival in stage III–IV patients?\",\"answer\":\"Chemotherapy plus radiotherapy was associated with improved overall survival (OS) and cancer-specific survival (CSS) versus chemotherapy alone in stage III–IV patients. Stage IV benefit appeared more context-dependent.\"}]","Patients With Stage III PLCNEC Advocated for Radiotherapy Combined With Chemotherapy While With Stage IV Focus on Individualized Management: Evidence From SEER | PDF",1790082507,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b4ef1ecb1a4e963ff528e74aa8d9a8e.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5906a1136135b1ac9469d5d2c033ccf7.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d28ebd5c0d4f6b68cdc0bc10f3b1e7f.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/909a26a09545c423c9bf53c63900951a.webp",980,1287]